Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

Bruna Corominas-Faja, Elisabet Cuyàs, Jesús Lozano-Sánchez, Sílvia Cufí, Sara Verdura, Salvador Fernández-Arroyo, Isabel Borrás-Linares, Begoña Martin-Castillo, Ángel G. Martin, Ruth Lupu, Alfons Nonell-Canals, Melchor Sanchez-Martinez, Vicente Micol, Jorge Joven, Antonio Segura-Carretero, Javier A. Menendez

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactorbinding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumorinitiating cell properties within BC populations.

Original languageEnglish (US)
Pages (from-to)601-613
Number of pages13
JournalCarcinogenesis
Volume39
Issue number4
DOIs
StatePublished - Apr 5 2018

Fingerprint

Neoplastic Stem Cells
Epigenomics
Breast Neoplasms
Methyltransferases
Methionine
Computer Simulation
Population
Neoplasms
Adenosine Triphosphate
Azacitidine
Aldehyde Dehydrogenase
Olive Oil
oleuropein
DNA
Phytochemicals
Sirolimus
Drug Discovery
Phenol
Methylation
Phosphotransferases

ASJC Scopus subject areas

  • Cancer Research

Cite this

Corominas-Faja, B., Cuyàs, E., Lozano-Sánchez, J., Cufí, S., Verdura, S., Fernández-Arroyo, S., ... Menendez, J. A. (2018). Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 39(4), 601-613. https://doi.org/10.1093/carcin/bgy023

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. / Corominas-Faja, Bruna; Cuyàs, Elisabet; Lozano-Sánchez, Jesús; Cufí, Sílvia; Verdura, Sara; Fernández-Arroyo, Salvador; Borrás-Linares, Isabel; Martin-Castillo, Begoña; Martin, Ángel G.; Lupu, Ruth; Nonell-Canals, Alfons; Sanchez-Martinez, Melchor; Micol, Vicente; Joven, Jorge; Segura-Carretero, Antonio; Menendez, Javier A.

In: Carcinogenesis, Vol. 39, No. 4, 05.04.2018, p. 601-613.

Research output: Contribution to journalArticle

Corominas-Faja, B, Cuyàs, E, Lozano-Sánchez, J, Cufí, S, Verdura, S, Fernández-Arroyo, S, Borrás-Linares, I, Martin-Castillo, B, Martin, ÁG, Lupu, R, Nonell-Canals, A, Sanchez-Martinez, M, Micol, V, Joven, J, Segura-Carretero, A & Menendez, JA 2018, 'Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells', Carcinogenesis, vol. 39, no. 4, pp. 601-613. https://doi.org/10.1093/carcin/bgy023
Corominas-Faja B, Cuyàs E, Lozano-Sánchez J, Cufí S, Verdura S, Fernández-Arroyo S et al. Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis. 2018 Apr 5;39(4):601-613. https://doi.org/10.1093/carcin/bgy023
Corominas-Faja, Bruna ; Cuyàs, Elisabet ; Lozano-Sánchez, Jesús ; Cufí, Sílvia ; Verdura, Sara ; Fernández-Arroyo, Salvador ; Borrás-Linares, Isabel ; Martin-Castillo, Begoña ; Martin, Ángel G. ; Lupu, Ruth ; Nonell-Canals, Alfons ; Sanchez-Martinez, Melchor ; Micol, Vicente ; Joven, Jorge ; Segura-Carretero, Antonio ; Menendez, Javier A. / Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. In: Carcinogenesis. 2018 ; Vol. 39, No. 4. pp. 601-613.
@article{6ce6eba2a172494a9608311f936517f7,
title = "Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells",
abstract = "Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactorbinding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumorinitiating cell properties within BC populations.",
author = "Bruna Corominas-Faja and Elisabet Cuy{\`a}s and Jes{\'u}s Lozano-S{\'a}nchez and S{\'i}lvia Cuf{\'i} and Sara Verdura and Salvador Fern{\'a}ndez-Arroyo and Isabel Borr{\'a}s-Linares and Bego{\~n}a Martin-Castillo and Martin, {{\'A}ngel G.} and Ruth Lupu and Alfons Nonell-Canals and Melchor Sanchez-Martinez and Vicente Micol and Jorge Joven and Antonio Segura-Carretero and Menendez, {Javier A.}",
year = "2018",
month = "4",
day = "5",
doi = "10.1093/carcin/bgy023",
language = "English (US)",
volume = "39",
pages = "601--613",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

AU - Corominas-Faja, Bruna

AU - Cuyàs, Elisabet

AU - Lozano-Sánchez, Jesús

AU - Cufí, Sílvia

AU - Verdura, Sara

AU - Fernández-Arroyo, Salvador

AU - Borrás-Linares, Isabel

AU - Martin-Castillo, Begoña

AU - Martin, Ángel G.

AU - Lupu, Ruth

AU - Nonell-Canals, Alfons

AU - Sanchez-Martinez, Melchor

AU - Micol, Vicente

AU - Joven, Jorge

AU - Segura-Carretero, Antonio

AU - Menendez, Javier A.

PY - 2018/4/5

Y1 - 2018/4/5

N2 - Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactorbinding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumorinitiating cell properties within BC populations.

AB - Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactorbinding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumorinitiating cell properties within BC populations.

UR - http://www.scopus.com/inward/record.url?scp=85045212469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045212469&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgy023

DO - 10.1093/carcin/bgy023

M3 - Article

C2 - 29452350

AN - SCOPUS:85045212469

VL - 39

SP - 601

EP - 613

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 4

ER -